"her2 breast cancer" trang 3 - tải miễn phí từ tailieunhanh
Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis

Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis
15    70    0
Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer

Association between gene expression profile of the primary tumor and chemotherapy response of metastatic breast cancer
8    63    1
Candidate methylation sites associated with endocrine therapy resistance in ER+/ HER2- breast cancer

Candidate methylation sites associated with endocrine therapy resistance in ER+/ HER2- breast cancer
15    34    1
Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: A case report and literature review

Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: A case report and literature review
8    59    1
Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States

Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States
12    30    1
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2- negative advanced stage breast cancer - a multicenter, randomized phase III trial

SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2- negative advanced stage breast cancer - a multicenter, randomized phase III trial
8    54    1
The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures

The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures
11    36    1
Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
8    63    1
A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer
9    47    1
Essential medicines for breast cancer in low and middle income countries

Essential medicines for breast cancer in low and middle income countries
8    54    1
Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries

Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries
15    38    1
The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: A retrospective study in 107 patients

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: A retrospective study in 107 patients
7    31    1
Multiple gene aberrations and breast cancer: Lessons from super-responders

Multiple gene aberrations and breast cancer: Lessons from super-responders
6    30    1
Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients

Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients
12    34    1
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients

Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients
12    44    1
Unraveling the chromosome 17 patterns of FISH in interphase nuclei: An in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells

Unraveling the chromosome 17 patterns of FISH in interphase nuclei: An in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells
14    45    1
Trastuzumab in advanced breast cancer – a decade of experience in Germany

Trastuzumab in advanced breast cancer – a decade of experience in Germany
9    32    1
MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway

MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway
13    54    1
Feline mammary basal-like adenocarcinomas: A potential model for human triple-negative breast cancer (TNBC) with basal-like subtype

Feline mammary basal-like adenocarcinomas: A potential model for human triple-negative breast cancer (TNBC) with basal-like subtype
12    42    1
Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status

Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status
11    50    1